AU Patent

AU2022291423A1 — Capsid inhibitors for the treatment of HIV

Assigned to Gilead Sciences Inc · Expires 2023-02-02 · 3y expired

What this patent protects

The present disclosure relates to compounds of Formula (Ia) and (Ib): F F F F F F F F F IN KN F N F N H H O H N N F N NS4 N-N o/ NN \\ F F F F F 0 0 (Ia) (Ib) 5 or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in …

USPTO Abstract

The present disclosure relates to compounds of Formula (Ia) and (Ib): F F F F F F F F F IN KN F N F N H H O H N N F N NS4 N-N o/ NN \\ F F F F F 0 0 (Ia) (Ib) 5 or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022291423A1
Jurisdiction
AU
Classification
—
Expires
2023-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.